PUBLISHER: Value Market Research | PRODUCT CODE: 2105705
PUBLISHER: Value Market Research | PRODUCT CODE: 2105705
Global Peptide And Oligonucleotide CDMO Market Size, Share, Trends & Growth Analysis Report 2026-2034
The global peptide and oligonucleotide CDMO market size is expected to reach USD 7.92 Billion in 2034 from USD 3.04 Billion in 2025, growing at a CAGR of 11.23 during 2026-2034.This market is experiencing rapid growth as pharmaceutical and biotechnology companies increasingly outsource the development and manufacturing of peptide- and oligonucleotide-based therapeutics. Contract development and manufacturing organizations provide specialized expertise, advanced production technologies, and regulatory support, enabling drug developers to accelerate clinical research and commercialization. Rising investments in precision medicine, expanding pipelines of RNA-based therapies, and increasing demand for complex biologics are driving market expansion. Continuous innovation in nucleic acid therapeutics is further strengthening industry growth.
CDMOs are investing in advanced synthesis technologies, automated manufacturing systems, and high-quality analytical capabilities to meet growing customer requirements. Increasing collaboration between biotechnology companies and contract manufacturers is improving production efficiency while reducing development timelines. Growing demand for personalized medicines, gene therapies, and rare disease treatments is creating substantial opportunities for specialized manufacturing providers. Regulatory compliance expertise and scalable manufacturing capacity remain key competitive advantages within the industry.
The future outlook remains highly promising as genetic medicine and targeted therapeutics continue advancing worldwide. Artificial intelligence-assisted process optimization, continuous manufacturing, and improved purification technologies will enhance production efficiency and product quality. Expanding clinical pipelines, increasing pharmaceutical outsourcing, and rising healthcare investments will support long-term market growth. Continuous innovation will establish peptide and oligonucleotide CDMOs as critical partners in the development of next-generation therapeutics.
Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:
Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.
Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.
Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.
Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.
Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.
Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.
Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.
Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.
MARKET SEGMENTATION
By Product
- Peptide CDMO
- Oligonucleotide CDMO
- Peptide-Oligonucleotide Conjugate CDMO
By Application
- Therapeutics
- Diagnostics
- Research & Discovery
- Vaccines
- Gene Editing
By Service Type
- Process Development
- GMP Manufacturing
- Analytical & Quality Control
- Fill-Finish & Packaging
- Regulatory & CMC Support
By End User
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Diagnostic Companies
- Gene & Cell Therapy Developers
- Others
COMPANIES PROFILED
- Bachem, PolyPeptide Group, Thermo Fisher (Patheon), Catalent, Merck KGaA, WuXi AppTec/STA, Lonza, Ajinomoto Bio-Pharma, Asymchem, Siegfried AG, CordenPharma, Eurogentec, GenScript, Almac Group, Integrated DNA Tech, Agilent, Eurofins Genomics, Senn Chemicals, Rentschler Biopharma, Novasep, Samsung Biologics, Enzene Biosciences, PharmaEssentia CDMO, Biosynth, AmideBio
TABLE OF CONTENTS
Chapter 1. PREFACE
- 1.1. Market Segmentation & Scope
- 1.2. Market Definition
- 1.3. Information Procurement
- 1.3.1 Information Analysis
- 1.3.2 Market Formulation & Data Visualization
- 1.3.3 Data Validation & Publishing
- 1.4. Research Scope and Assumptions
- 1.4.1 List of Data Sources
Chapter 2. EXECUTIVE SUMMARY
- 2.1. Market Snapshot
- 2.2. Segmental Outlook
- 2.3. Competitive Outlook
Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK
- 3.1. Market Lineage Outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Value Chain Analysis
- 3.4. Regulatory Framework
- 3.4.1 Standards & Compliance
- 3.4.2 Regulatory Impact Analysis
- 3.5. Market Dynamics
- 3.5.1 Market Drivers
- 3.5.2 Market Restraints
- 3.5.3 Market Opportunities
- 3.5.4 Market Challenges
- 3.6. Porter's Five Forces Analysis
- 3.7. PESTLE Analysis
Chapter 4. GLOBAL PEPTIDE AND OLIGONUCLEOTIDE CDMO MARKET: BY PRODUCT 2022-2034 (USD MN)
- 4.1. Market Analysis, Insights and Forecast Product
- 4.2. Peptide CDMO Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.3. Oligonucleotide CDMO Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.4. Peptide-Oligonucleotide Conjugate CDMO Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 5. GLOBAL PEPTIDE AND OLIGONUCLEOTIDE CDMO MARKET: BY APPLICATION 2022-2034 (USD MN)
- 5.1. Market Analysis, Insights and Forecast Application
- 5.2. Therapeutics Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.3. Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.4. Research & Discovery Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.5. Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.6. Gene Editing Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 6. GLOBAL PEPTIDE AND OLIGONUCLEOTIDE CDMO MARKET: BY SERVICE TYPE 2022-2034 (USD MN)
- 6.1. Market Analysis, Insights and Forecast Service Type
- 6.2. Process Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.3. GMP Manufacturing Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.4. Analytical & Quality Control Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.5. Fill-Finish & Packaging Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.6. Regulatory & CMC Support Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 7. GLOBAL PEPTIDE AND OLIGONUCLEOTIDE CDMO MARKET: BY END USER 2022-2034 (USD MN)
- 7.1. Market Analysis, Insights and Forecast End User
- 7.2. Pharmaceutical & Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 7.3. Academic & Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 7.4. Diagnostic Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 7.5. Gene & Cell Therapy Developers Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 7.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 8. GLOBAL PEPTIDE AND OLIGONUCLEOTIDE CDMO MARKET: BY REGION 2022-2034 (USD MN)
- 8.1. Regional Outlook
- 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.2.1 By Product
- 8.2.2 By Application
- 8.2.3 By Service Type
- 8.2.4 By End User
- 8.2.5 United States
- 8.2.6 Canada
- 8.2.7 Mexico
- 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.3.1 By Product
- 8.3.2 By Application
- 8.3.3 By Service Type
- 8.3.4 By End User
- 8.3.5 United Kingdom
- 8.3.6 France
- 8.3.7 Germany
- 8.3.8 Italy
- 8.3.9 Russia
- 8.3.10 Rest Of Europe
- 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.4.1 By Product
- 8.4.2 By Application
- 8.4.3 By Service Type
- 8.4.4 By End User
- 8.4.5 India
- 8.4.6 Japan
- 8.4.7 South Korea
- 8.4.8 Australia
- 8.4.9 South East Asia
- 8.4.10 Rest Of Asia Pacific
- 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.5.1 By Product
- 8.5.2 By Application
- 8.5.3 By Service Type
- 8.5.4 By End User
- 8.5.5 Brazil
- 8.5.6 Argentina
- 8.5.7 Peru
- 8.5.8 Chile
- 8.5.9 Rest of Latin America
- 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.6.1 By Product
- 8.6.2 By Application
- 8.6.3 By Service Type
- 8.6.4 By End User
- 8.6.5 Saudi Arabia
- 8.6.6 UAE
- 8.6.7 Israel
- 8.6.8 South Africa
- 8.6.9 Rest of the Middle East And Africa
Chapter 9. COMPETITIVE LANDSCAPE
- 9.1. Recent Developments
- 9.2. Company Categorization
- 9.3. Supply Chain & Channel Partners (based on availability)
- 9.4. Market Share & Positioning Analysis (based on availability)
- 9.5. Vendor Landscape (based on availability)
- 9.6. Strategy Mapping
Chapter 10. COMPANY PROFILES OF GLOBAL PEPTIDE AND OLIGONUCLEOTIDE CDMO INDUSTRY
- 10.1. Top Companies Market Share Analysis
- 10.2. Company Profiles
- 10.2.1 Bachem
- 10.2.2 PolyPeptide Group
- 10.2.3 Thermo Fisher (Patheon)
- 10.2.4 Catalent
- 10.2.5 Merck KGaA
- 10.2.6 WuXi AppTec/STA
- 10.2.7 Lonza
- 10.2.8 Ajinomoto Bio-Pharma
- 10.2.9 Asymchem
- 10.2.10 Siegfried AG
- 10.2.11 CordenPharma
- 10.2.12 Eurogentec
- 10.2.13 GenScript
- 10.2.14 Almac Group
- 10.2.15 Integrated DNA Tech
- 10.2.16 Agilent
- 10.2.17 Eurofins Genomics
- 10.2.18 Senn Chemicals
- 10.2.19 Rentschler Biopharma
- 10.2.20 Novasep
- 10.2.21 Samsung Biologics
- 10.2.22 Enzene Biosciences
- 10.2.23 PharmaEssentia CDMO
- 10.2.24 Biosynth
- 10.2.25 AmideBio
